Explanipedia

HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast Cancer Open

Véronique Dièras, Giuseppe Curigliano, Miguel Martín, Florence Lerebours, Junji Tsurutani , et al. · 2025

Purpose The HER2CLIMB-05 study ( ClinicalTrials.gov identifier: NCT05132582 ) is investigating the efficacy and safety of adding tucatinib to trastuzumab and pertuzumab as first-line (1L) maintenance therapy in patients with human epiderma…

NON-INTRAVENOUS CHEMOTHERAPY-SPARING TRIPLET OF DALPICICLIB/PYROTINIB/ENDOCRINE THERAPY WAS PROMISING IN WOMEN WITH HR-POSITIVE, HER2-POSITIVE ADVANCED BREAST CANCER (PLEASURABLE): A MULTICENTRE, OPEN-LABEL, PHASE 2 TRIAL Open

Xichun Hu, Jian Zhang, Yanchun Meng, Biyun Wang, Xinhong Wu , et al. · 2025

A Phase I open-label study to assess the pharmacokinetics, safety, and tolerability of capivasertib alone or in combination with paclitaxel in Chinese patients with advanced solid tumors Open

Jian Zhang, Xiaojun Liu, Yiqun Du, Yuxin Mu, Yanchun Meng , et al. · 2025

Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial Open

Jian Zhang, Yanchun Meng, Biyun Wang, Xinhong Wu, Hongmei Zheng , et al. · 2025

Background Combination of HER2-targeted therapy and endocrine therapy offers a more tolerable alternative to HER2-targeted chemotherapy regimens for estrogen receptor (ER)-positive, HER2-positive advanced breast cancer (ABC), but with comp…

Potential regulatory role of the m<sup>6</sup>A-lncRNA axis in breast cancer: molecular mechanisms and therapeutic implications Open

Di Chen, Jinyan Wang, Xichun Hu, Shu Liu · 2025

N6-methyladenosine (m ⁶A) modification, the most prevalent internal modification in eukaryotic messenger RNAs (mRNAs), has emerged as a crucial regulator of various biological processes. This reversible epigenetic modification i…

Analytical and clinical validation of PATHWAY HER2 (4B5) assay for assessment of HER2-low/HER2-ultralow status and eligibility for trastuzumab deruxtecan in DESTINY-Breast06 Open

Rana Shami, Roberto Salgado, A. Bardia, G. Curigliano, Xichun Hu , et al. · 2025

For patients with HER2 IHC 0 mBC, rescoring and/or retesting with the Roche HER2 4B5 assay is encouraged to determine eligibility for T-DXd.

A phase I dose-escalation and dose-expansion study of tibremciclib, a novel CDK4/6 inhibitor, monotherapy and in combination with fulvestrant in HR-positive/HER2-negative advanced breast cancer Open

Jian Zhang, Rujiao Liu, Shegan Gao, W. Chen, Xiaozhe Han , et al. · 2025

Advancements in Diagnostics and Therapeutics for Cancer of Unknown Primary in the Era of Precision Medicine Open

Ting Zhao, Xiaowei Zhang, Xin Liu, Qifeng Wang, Xichun Hu , et al. · 2025

Cancer of unknown primary (CUP), a set of histologically confirmed metastases that cannot be identified or traced back to its primary despite comprehensive investigations, accounts for 2–5% of all malignancies. CUP is the fourth leading ca…

Updated efficacy and safety of HLX02 versus reference trastuzumab in metastatic HER2-positive breast cancer: A randomized phase III equivalence trial Open

Binghe Xu, Qingyuan Zhang, Tao Sun, Wei Li, Yuee Teng , et al. · 2025

A multicenter, randomized, double-blind trial comparing LY01011, a biosimilar, with denosumab (Xgeva®) in patients with bone metastasis from solid tumors Open

Mingchuan Zhao, Xichun Hu, Panpan Zhuang, Aiping Zeng, Yan Yu , et al. · 2025

Multimodal Parameters for Diagnosis of Putative Primaries of Cancer of Unknown Primary Open

S L Pan, Jinyan Wang, Jing Liu, Si‐Min He, Xin Liu , et al. · 2025

Patient-reported quality of life in Asian patients with ER+/HER2− advanced breast cancer treated with palbociclib plus letrozole in the PALOMA-4 trial Open

Binghe Xu, Xichun Hu, Wei Li, Tao Sun, Kunwei Shen , et al. · 2024

Background: Palbociclib plus an aromatase inhibitor is approved for treatment of patients with ER+/HER2− advanced breast cancer (ABC). In the PALOMA-4 trial, adding palbociclib to letrozole prolonged median progression-free survival in Asi…

Entrectinib versus crizotinib in Asian patients with ROS1-positive non-small cell lung cancer: A matching-adjusted indirect comparison Open

Yongfeng Yu, Yun Fan, Xiaorong Dong, Juan Li, Yan Yu , et al. · 2024

The outcomes in this MAIC study including Asian patients with ROS1-positive NSCLC showed a trend for greater clinical benefit with entrectinib versus crizotinib. These findings may contribute to better-informed treatment decisions.

Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2− advanced breast cancer: Final results of the randomized phase III MONARCH plus trial Open

Xichun Hu, Qingyuan Zhang, Tao Sun, Yongmei Yin, Huiping Li , et al. · 2024

Background: In the interim analysis of MONARCH plus, adding abemaciclib to endocrine therapy (ET) improved progression-free survival (PFS) and objective response rate (ORR) in predominantly Chinese postmenopausal women with HR+/HER2− advan…

First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors Open

Jian Zhang, Yiqun Du, Yanchun Meng, Xiaojun Liu, Yuxin Mu , et al. · 2024

DP303c is a HER2-targeted ADC with a cleavable linker-MMAE payload. Previous in vitro studies demonstrated that DP303c showed similar or better antitumor activity than T-DM1 in xenograft models. This was a multicenter, dose escalation and …

ARX788 Versus Lapatinib Plus Capecitabine in the Second-Line Treatment of HER2-Positive Advanced Breast Cancer (ACE-Breast-02): A Multicentre, Open-Label, Phase III, Randomised Controlled Trial Open

Xichun Hu, Qingyuan Zhang, Leiping Wang, Jian Zhang, Quchang Ouyang , et al. · 2024

OR98 UPDATED OVERALL SURVIVAL (OS) OUTCOMES FROM THE PHASE 3 PHOEBE TRIAL OF PYROTINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2-POSITIVE METASTATIC BREAST CANCER Open

Binghe Xu, Fei Ma, Min Yan, Xichun Hu, Jifeng Feng , et al. · 2023

Results: Interestingly, in subgroup analysis of rs1045642 in ABCB1 gene, a significant difference was found with a greater progression free survival (PFS) of the AA homozygous group compared to the heterozygous alleles ( p = 0.002, with Bo…

Consensus on clinical diagnosis and medical treatment of HER2-low breast cancer (2022 edition) Open

Bu Hong, Ying Fan, Fan Zhaoqing, Xichun Hu, Man Li , et al. · 2023

Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer Open

Guang Ma, Shuhui You, Yizhao Xie, Bingxin Gu, Cheng Liu , et al. · 2023

Objective Intra-tumoral heterogeneity of 18 F‐fluorodeoxyglucose ( 18 F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastati…

Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial Open

Jun Cao, Yuee Teng, Huiping Li, Lili Zhang, Quchang Ouyang , et al. · 2023

Preclinical and clinical activity of DZD1516, a full blood–brain barrier-penetrant, highly selective HER2 inhibitor Open

Jian Zhang, Nicholas P. McAndrew, Xiaojia Wang, Yiqun Du, Brian DiCarlo , et al. · 2023

Background Patients with HER2-positive metastatic breast cancer (MBC) are at high risk of developing central nervous system (CNS) metastases. A potent and selective HER2 inhibitor with good blood–brain barrier (BBB) penetration is highly d…

GepLiver: an integrative liver expression atlas spanning developmental stages and liver disease phases Open

Ziteng Li, Hena Zhang, Qin Li, Wanjing Feng, Xiya Jia , et al. · 2023

Chronic liver diseases usually developed through stepwise pathological transitions under the persistent risk factors. The molecular changes during liver transitions are pivotal to improve liver diagnostics and therapeutics yet still remain…

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer Open

Nicholas C. Turner, Mafalda Oliveira, Sacha J. Howell, Florence Dalenc, Javier Cortés , et al. · 2023

Capivasertib-fulvestrant therapy resulted in significantly longer progression-free survival than treatment with fulvestrant alone among patients with hormone receptor-positive advanced breast cancer whose disease had progressed during or a…

Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma Open

Qi Zhang, Jian Zhang, Haijun Zhong, Ying Yuan, Lei Yang , et al. · 2023

Phase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours Open

Jian Zhang, Rujiao Liu, Shuiping Gao, Wenhua Li, Yang Chen , et al. · 2023

Supplementary Figure from First-in-human HER2-targeted Bispecific Antibody KN026 for the Treatment of Patients with HER2-positive Metastatic Breast Cancer: Results from a Phase I Study Open